Child Health Imprints Secures $2.4M Series A to Advance IoT-Powered Neonatal Intensive Care Units

On November 4, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that Child Health Imprints (CHIL), a healthcare information technology company, announced the completion of its $2.4 million Series A financing round. The round was led by venture capital firms HealthX Capital and Seeds Capital, with participation from Enterprise Singapore.

It is reported that CHIL will use the funds from this financing to enhance its comprehensive Neonatal Intensive Care Units (NICUs) in the Asia-Pacific region and improve its medical care standards.

CHIL, established in 2018 and headquartered in central Singapore, is a healthcare information technology company. The company is dedicated to researching the Internet of Things (IoT) and leveraging cutting-edge technologies such as artificial intelligence and predictive analytics to transform and enhance Neonatal Intensive Care Units (NICUs), thereby improving health outcomes for neonatal patients. CHIL has developed the NICU Cloud platform based on IoT technology. This platform connects various devices, automatically captures real-time clinical data, and transmits it to the cloud platform, providing healthcare professionals with a comprehensive pediatric healthcare solution.

The Neonatal Intensive Care Unit (NICU) is a specialized ward dedicated to the intensive care of critically ill newborns, requiring advanced medical equipment and adequate nursing staff. This unit enhances the quality of medical care and helps reduce complications in patients, thereby lowering neonatal mortality rates. The NICU is primarily used for life support in high-risk newborns, postoperative monitoring and management, and the care of premature infants. Medical personnel can promptly provide emergency rescue and treatment for infants suffering from conditions such as respiratory failure and hemolytic disease, ensuring the survival and well-being of these patients.

CHIL specializes in clinical neonatal care and early diagnosis of critical conditions, dedicated to improving the overall quality of healthcare for newborns. Currently, the company operates 25 intensive care units in local Indian hospitals, including Sir Gangaram Hospital and Apollo Hospitals. CHIL aims to expand its business across various regions in India and further extend into international markets such as Japan and South Korea.

“CHIL Co-founder and CEO Harpreet Singh stated, ‘We are committed to improving neonatal health in Southeast Asia. Moving forward, CHIL will venture into the emerging neonatal ecosystem sector and bring our technological products to the international market.’”

HXC, established in 2017 and headquartered in Singapore, is Asia’s first health-tech venture capital firm. Jointly founded by Jungle Ventures, a leading Singapore-based venture capital firm, and Apollo Hospitals, India’s largest healthcare provider, HXC is dedicated to providing financial support to emerging healthcare companies in the Southeast Asian and Indian markets.

Seeds Capital, established in 2008 and headquartered in Singapore, is a venture capital firm affiliated with the Singapore government. The firm focuses on the chemicals, clean technology, education, engineering, food, beverage, and healthcare sectors. Since its inception, Seeds Capital has completed 13 investments.

Established in April 2018, Enterprise Singapore is a statutory board under the Ministry of Trade and Industry, dedicated to advocating for enterprise development. The agency primarily provides financial support and strategic guidance to small and medium-sized enterprises (SMEs) to drive the development, innovation, transformation, and internationalization of Singapore’s industries.

(Compiled by Xu Xiaoxue)